Mechanistically, ALKBH5 removes the m6A marks, increases the stability of mRNA, and enhances the expression of plasmacytoma variant translocation one through inhibiting its YTHDF2 binding, resulting in increased OS cell proliferation rates both in vitro and in vivo (Int et al., 2020). Here, ALKBH5 is linked to plasmacytoma.